MoleMap Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Private

  • Employees
  • 103

Employees

  • Latest Deal Type
  • PE Growth

  • Financing Rounds
  • 6

  • Investments
  • 1

MoleMap General Information

Description

Operator of an advanced melanoma detection program designed to identify skin cancer as early as possible. The company offers skin checks, full-body mole maps and follow-ups as well as workplace wellness and other medical services through imaging and telemedicine technologies, thereby helping clients manage skin damage risk.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • Unit L/383 Khyber Pass Road
  • Newmarket
  • Auckland
  • New Zealand
+64 09
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Clinics/Outpatient Services
Corporate Office
  • Unit L/383 Khyber Pass Road
  • Newmarket
  • Auckland
  • New Zealand
+64 09

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MoleMap Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MoleMap‘s full profile, request access.

Request a free trial

MoleMap Patents

MoleMap Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10242442-B2 Detection of outlier lesions based on extracted features from skin images Inactive 27-Oct-2016
US-10586330-B2 Detection of outlier lesions based on extracted features from skin images Active 27-Oct-2016
US-20180122065-A1 Detection of outlier lesions based on extracted features from skin images Active 27-Oct-2016
US-20190147594-A1 Detection of outlier lesions based on extracted features from skin images Active 27-Oct-2016
US-10282843-B2 System and method for lesion analysis and recommendation of screening checkpoints for reduced risk of skin cancer Inactive 27-Oct-2016 G06T7/0016
To view MoleMap’s complete patent history, request access »

MoleMap Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MoleMap Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore MoleMap‘s full profile, request access.

Request a free trial

MoleMap Investments (1)

MoleMap’s most recent deal was a Buyout/LBO with Spotscreen. The deal was made on 07-May-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Spotscreen 07-May-2026 Buyout/LBO Educational and Training Services (B2C)
To view MoleMap’s complete investments history, request access »

MoleMap Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Spotscreen Perth, Australia 2011

MoleMap FAQs

  • When was MoleMap founded?

    MoleMap was founded in 1997.

  • Where is MoleMap headquartered?

    MoleMap is headquartered in Auckland, New Zealand.

  • What is the size of MoleMap?

    MoleMap has 103 total employees.

  • What industry is MoleMap in?

    MoleMap’s primary industry is Diagnostic Equipment.

  • Is MoleMap a private or public company?

    MoleMap is a Private company.

  • What is MoleMap’s current revenue?

    The current revenue for MoleMap is .

  • Who are MoleMap’s investors?

    Pioneer Capital and New Zealand Government have invested in MoleMap.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process